Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | HTR3A | P46098 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7405359 | 0.98 | GAA (0.97) | GAAKDM4EHTR4CYP3A4CYP1A2 | |
| SCHEMBL31321292 | 0.91 | GAA (0.82) | GAAKDM4EHTR4CYP3A4CYP1A2 | |
| SCHEMBL8292456 | 0.88 | GAA (0.79) | GAAKDM4EHTR4CYP3A4CYP1A2 | |
| SCHEMBL7853424 | 0.86 | GAA (0.76) | GAAKDM4EHTR4CYP3A4CYP1A2 | |
| SCHEMBL7419408 | 0.85 | GAA (0.74) | GAAKDM4ESMN1; SMN2GLANPC1 | |
| SCHEMBL6473999 | 0.85 | GAA (0.74) | GAAKDM4EHTR4CYP3A4CYP1A2 | |
| SCHEMBL29424850 | 0.85 | GAA (0.74) | GAAKDM4EHTR4CYP3A4CYP1A2 | |
| SCHEMBL9379986 | 0.85 | GAA (0.74) | GAAHTR4CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL725809 | 0.84 | GAA (0.73) | GAAHTR4CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL7280230 | 0.84 | GAA (0.73) | GAAHTR4CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606523-B2 | Deuterated organic compounds and uses thereof | ENGRAIL THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| CN-119977828-A | Methoxychlor-pup Process for the preparation of amines | 河南优凯制药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119977827-A | Methoxychlor-pram intermediate and preparation method and application thereof | 河南优凯制药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250091990-A1 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | ENGRAIL THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2025-02-06 | — | — | US | disclosed |
| US-20250011280-A1 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | ENGRAIL THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4460292-A1 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | Engrail Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-4460490-A1 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | Engrail Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-118804910-A | Deuterated organic compounds and use thereof | 恩格雷尔治疗有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118804746-A | Deuterated organic compounds and use thereof | 恩格雷尔治疗有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-5063230-A | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-11-05 | — | — | US | disclosed |
| WO-1991004738-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| US-4959485-A | 5-HT3 ANTAGONISTS | RORER PHARMACEUTICAL CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
| WO-1990006113-A1 | SUBSTITUTED SATURATED AND UNSATURATED INDOLE QUINOLINE AND BENZAZEPINE CARBOXAMIDES AND THEIR USE AS PHARMACOLOGICAL AGENTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1990-06-14 | — | — | WO | disclosed |
| US-4920219-A | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4914117-A | ANTIDEPRESSANTS, CENTRAL NERVOUS SYSTEM ACTIVATORS; DOPAMINE ANTAGONISTS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLE DE L'ILE-D-FRANCE (FR) | 1990-04-03 | — | — | US | disclosed |
| WO-1989010364-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-11-02 | — | — | WO | disclosed |
| EP-0339950-A2 | Dibenzofurancarboxamides, their use as pharmaceutical agents, a composition containing the same, and a process for the preparation thereof | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| US-4863921-A | Dibenzofurancarboxamides and their pharmaceutical compositions and methods | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4835172-A | Novel benzamides, intermediates and process for the preparation and therapeutic use thereof | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | GAA 154/4885KDM4E 2905/4885HTR4 4266/4885 |
| US-20250091990-A1 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | DRD1, DRD4, DRD2 | GAA 2151/4885KDM4E 3482/4885HTR4 13/4885 |
| US-12606523-B2 | Deuterated organic compounds and uses thereof | DRD1, DRD2, DRD3 | GAA 4676/4885KDM4E 3058/4885HTR4 37/4885 |
| US-20250011280-A1 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | DBH, DRD1, OPRD1 | GAA 1451/4885KDM4E 3024/4885HTR4 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.